ReviewImmunity2017
The Broad Spectrum of Human Natural Killer Cell Diversity.
Open access · bronzeAbstract readReview
In one paragraph
Review in Immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 448 papers.
0numbers the graph read from it
0cells of the map it votes in
448citing papers in PubMed
20.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
448 citing papers in PubMed, 678 citations in OpenAlex.
- Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.Signal transduction and targeted therapy · 2024Trial
- Natural Killer Cells and Innate Lymphoid Cells Immunoprofiling.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- Synovial Fluid Immune Cell Landscape in Juvenile Idiopathic Arthritis.European journal of immunology · 2026Article
- Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.Inflammopharmacology · 2026Review
- Identification of elements determiningiScience · 2026Article
- How past transient viremia shape natural killer cells' antibody-dependent functions in youth with perinatal HIV.iScience · 2026Article
- Article
- Immunophenotyping challenges in the diagnosis of NK-LGLL.Blood advances · 2026Article
- Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.Journal for immunotherapy of cancer · 2026Article
- Bridging the gap: neuroinflammation and the dawn of precision medicine in amyotrophic lateral sclerosis.Translational neurodegeneration · 2026Review
- Maternal NKG2D-mediated immune activation shapes fetal neural development.Molecular psychiatry · 2026Article
- Metabolic Checkpoints in Cutaneous Squamous Cell Carcinoma: ACSL1 and PPARD Orchestrate Lipid-Ferroptosis Crosstalk via Keratinocyte Remodeling.Applied biochemistry and biotechnology · 2026Article
- From single cell analysis to 3D micro physiological systems: microfluidic tools integrating cancer cell targets for delineating natural killer cell biology.Microsystems & nanoengineering · 2026Review
- CD49aScientific reports · 2026Article
- Role of Innate Lymphoid Cells in Chronic Rhinosinusitis: Insights from Tissue and Peripheral Blood Flow Cytometric Analysis.Advances in respiratory medicine · 2026Article
- Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors.Cancer immunology research · 2026Article
- Natural killer cells and regulatory T cells in aneurysmal subarachnoid hemorrhage in peripheral blood and cerebrospinal fluid - a pilot study.Fluids and barriers of the CNS · 2026Observational
- Alveolar macrophage-neutrophil crosstalk in acute lung injury: mechanisms, feedback loops, and therapeutic opportunities.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Natural Killer Cell Assays: Clinical Applications and Future Directions.Annals of laboratory medicine · 2026Review
388 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA. Electronic address: aharon.freud@osumc.edu.
Bethany L Mundy-BosseDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Jianhua YuDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Michael A CaligiuriDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA. Electronic address: michael.caligiuri@osumc.edu.
The Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0MIL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5MElucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MEnhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8MIL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4MNCI NIH HHS L30 CA199447NCI NIH HHS P01 CA095426NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA185301NCI NIH HHS R01 CA208353NCI NIH HHS R37 CA068458NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
Natural killer (NK) cells provide protection against infectious pathogens and cancer. For decades it has been appreciated that two major NK cell subsets (CD56
Indexed as
CD56 AntigenHumansKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily ANK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DCD56 AntigenNK Cell Lectin-Like Receptor Subfamily ANK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily D
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.